Metopirone

Metyrapone, the active ingredient in Metopirone, is a 11‑beta‑hydroxylase inhibitor presented as a tablet for oral use. It is employed in the management of Cushing's syndrome, in diagnostic testing of adrenal function, and as adjunct therapy for adrenal insufficiency. GNH USA supplies Metopirone as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metopirone acts on adrenal steroid synthesis pathways and is indicated for several endocrine conditions.

Cushing's syndrome: reduces excess cortisol production to improve clinical symptoms. Diagnostic testing of adrenal function: blocks cortisol synthesis to assess adrenal reserve and ACTH response. Adrenal insufficiency (adjunct therapy): used alongside glucocorticoid replacement to aid evaluation and management of adrenal disorders.

Adverse reactions to Metopirone may vary in frequency and severity.

Common Side Effects: - Nausea or vomiting - Dizziness or headache - Fatigue or weakness - Abdominal discomfort - Mild hypertension

Serious or Rare Side Effects: - Adrenal insufficiency with severe cortisol deficiency - Significant hypertension or hypertensive crisis - Electrolyte disturbances such as hypokalemia - Allergic reactions including rash or angioedema - Hepatic dysfunction or elevated liver enzymes

Metopirone requires careful monitoring and specific safety considerations.

Pregnancy: safety not established; use only if benefits outweigh risks. Breastfeeding: unknown excretion; consider potential infant exposure. Renal impairment: monitor renal function and electrolytes closely. Cardiovascular disease: observe blood pressure as drug may increase hypertension. Drug interactions: review concomitant medications that affect steroid metabolism. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Metyrapone can interact with several drug classes, necessitating vigilance.

Major Interactions (Avoid): - Potent CYP3A4 inducers (e.g., rifampicin): may markedly reduce efficacy. - Concurrent high‑dose glucocorticoids: can mask signs of adrenal insufficiency.

Moderate Interactions (Monitor Closely): - Antihypertensive agents: metyrapone may elevate blood pressure. - Diuretics: risk of worsening electrolyte imbalances. - Oral contraceptives: possible alteration of steroid metabolism.